Isabel Pinto Amorim das Virgens

Ms. Isabel Pinto Amorim das Virgens


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Andras KubikAndras Kubik
Andras Kubik
IVIsabel Pinto Amorim das Virgens
Isabel Pinto Amorim das Virgens
ASAnett Szabó
Anett Szabó
MVMelinda Váradi
Melinda Váradi
ACAnita Csizmarik
Anita Csizmarik
TSTibor Szarvas
Tibor Szarvas
Lymph node (LN) status is the most significant prognostic factor for invasive urothelial bladder cancer (UBC); however, the optimal extent of LN dissection (LND) is debated. We assessed circulating matrix metalloproteinase-7 (MMP-7) as a prognostic factor and decision-making marker for the extent of LND. Preoperative serum MMP-7 levels were determined in two independent UBC cohorts (n = 188; n = 68) and in one control cohort (n = 97) by using the ELISA method. A systematic review and meta-analysis on the prognostic role of circulating pretreatment MMP-7 levels were performed. Serum MMP-7 levels were higher in patients compared to controls (p < 0.001) with the highest levels in LN-positive cases. Half of LN-positive UBC patients had low MMP-7 levels, whereas the survival of LN-negative patients with high serum MMP-7 findings was poor. MMP-7 levels were independently associated with poor survival in both cohorts (p = 0.006, p < 0.001). Accordingly, our systematic review of six eligible publications revealed a 2.5-fold higher mortality risk in patients with high MMP-7 levels. In conclusion, preoperative MMP-7 level is a validated and independent prognostic factor in urothelial cancer. It cannot be used to decide between regional or extended LND but may be useful in identifying LN-negative high-risk patients with potentially undetected metastases.

4 November 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
RVRita Zsuzsanna Vajna
Rita Zsuzsanna Vajna
AGAndrás Mihály Géczi
András Mihály Géczi
IVIsabel Pinto Amorim das Virgens
Isabel Pinto Amorim das Virgens
SVSzilárd Váncsa
Szilárd Váncsa
NANandor Acs
Nandor Acs
LSLevente Sára
Levente Sára
Background/Objectives: Nutritional preparations are used by women with polycystic ovary syndrome (PCOS), but their short-term metabolic effects are uncertain. Methods: MEDLINE, Embase and the Cochrane Library were searched up to 4 December 2025 (PROSPERO: CRD42023424883). Between-group mean differences (MDs) in change from baseline were pooled separately for each intervention–comparator pair (restricted maximum likelihood, modified Hartung–Knapp 95% confidence intervals [CIs]). Risk of bias was assessed with the Cochrane risk-of-bias tool for randomized trials, version 2 (RoB 2) and certainty with GRADE (Grading of Recommendations Assessment, Development and Evaluation). Several analyses were post hoc. Results: Of 40 reports of 38 trials, 28 reports (26 trials) entered the primary analyses. Of 62 pooled estimates, two excluded no difference: 25-hydroxyvitamin D (25(OH)D) increased with vitamin D3 (five trials, 298 participants, MD +15.19 ng/mL, 95% CI 8.36 to 22.02, very low certainty) and homeostatic model assessment of insulin resistance (HOMA-IR) decreased with cinnamon (three trials, 185 participants, MD −1.03, 95% CI −1.97 to −0.09, low certainty), but this was not robust to omitting any single trial. Vitamin D3 did not clearly change fasting insulin or glucose. D-chiro-inositol estimates were highly imprecise. Of 176 graded estimates, 67 were of low and 109 of very low certainty. Conclusions: Apart from the expected rise in 25(OH)D, nutritional preparations showed no robust short-term metabolic effect in PCOS. The evidence does not support ranking preparations or treatment recommendations.